|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions |
EXP |
7-chlorokynurenic acid inhibits the reaction [Cocaine results in increased phosphorylation of and results in increased activity of CAMK2A protein] |
CTD |
PMID:17609678 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
|
G |
Dhodh |
dihydroorotate dehydrogenase (quinone) |
multiple interactions decreases activity |
EXP ISO |
brequinar inhibits the reaction [DHODH protein results in increased metabolism of 4,5-dihydroorotic acid]; brequinar inhibits the reaction [DHODH protein results in increased metabolism of Quinones]; brequinar inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid] brequinar results in decreased activity of DHODH protein |
CTD |
PMID:9776318 PMID:9802339 PMID:10658902 |
|
NCBI chr19:37,551,858...37,573,327
Ensembl chr19:37,558,177...37,591,654
|
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
ISO |
Ciprofloxacin results in decreased expression of ABCC2 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
ISO |
Ciprofloxacin results in increased expression of ABCC3 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases export multiple interactions increases expression |
ISO |
ABCC4 protein results in increased export of Ciprofloxacin [Ciprofloxacin results in increased expression of ABCC4 protein] which results in decreased uptake of Ciprofloxacin Ciprofloxacin results in increased expression of ABCC4 mRNA; Ciprofloxacin results in increased expression of ABCC4 protein [Ciprofloxacin results in increased expression of ABCC4 protein] which results in decreased uptake of Ciprofloxacin; Gemfibrozil inhibits the reaction [[Ciprofloxacin results in increased expression of ABCC4 protein] which results in decreased uptake of Ciprofloxacin] |
CTD |
PMID:19307362 PMID:22162766 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
ISO |
Ciprofloxacin results in increased expression of ABCG2 protein |
CTD |
PMID:26947806 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
ISO |
Ciprofloxacin results in increased phosphorylation of AKT1 protein |
CTD |
PMID:26947806 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression |
ISO |
Ciprofloxacin results in increased expression of ALDH1A1 protein |
CTD |
PMID:26947806 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases localization increases expression |
ISO |
BCL2 protein inhibits the reaction [Ciprofloxacin results in increased localization of BAX protein] Ciprofloxacin results in increased expression of BAX protein |
CTD |
PMID:10741713 PMID:11832715 PMID:11875713 PMID:12632069 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Etoposide co-treated with Ciprofloxacin] results in decreased expression of BCL2 protein; BCL2 protein inhibits the reaction [Ciprofloxacin results in increased localization of BAX protein] |
CTD |
PMID:11832715 PMID:12063570 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO EXP |
Ciprofloxacin results in increased cleavage of and results in increased activity of CASP3 protein Ciprofloxacin results in increased activity of CASP3 protein |
CTD |
PMID:10741713 PMID:11832715 PMID:11875713 PMID:12632069 PMID:30273099 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Ciprofloxacin results in increased activity of CASP8 protein |
CTD |
PMID:11875713 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO EXP |
Ciprofloxacin results in increased activity of CASP9 protein |
CTD |
PMID:11875713 PMID:30273099 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases activity multiple interactions |
EXP |
Ciprofloxacin results in decreased activity of CAT protein Quercetin inhibits the reaction [Ciprofloxacin results in decreased activity of CAT protein] |
CTD |
PMID:25902267 PMID:25929518 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
increases expression |
ISO |
Ciprofloxacin results in increased expression of CAV1 protein |
CTD |
PMID:26947806 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression increases expression |
ISO EXP |
Ciprofloxacin results in decreased expression of CCNB1 protein Ciprofloxacin results in increased expression of CCNB1 mRNA; Ciprofloxacin results in increased expression of CCNB1 protein |
CTD |
PMID:10741713 PMID:18512786 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Ciprofloxacin results in decreased expression of CCNE1 protein |
CTD |
PMID:10741713 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cd44 |
CD44 molecule |
increases expression |
ISO |
Ciprofloxacin results in increased expression of CD44 protein |
CTD |
PMID:26947806 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
increases expression |
EXP |
Ciprofloxacin results in increased expression of CDK1 mRNA; Ciprofloxacin results in increased expression of CDK1 protein |
CTD |
PMID:18512786 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases phosphorylation |
ISO |
Ciprofloxacin results in decreased phosphorylation of CDK2 protein |
CTD |
PMID:10741713 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
ISO |
Ciprofloxacin results in decreased expression of CDKN1A; Ciprofloxacin results in decreased expression of CDKN1A protein |
CTD |
PMID:10741713 PMID:12063570 PMID:12632069 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
multiple interactions |
ISO |
Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased activity of CEBPD mRNA] |
CTD |
PMID:11052920 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
EXP |
Ciprofloxacin results in increased expression of CHEK1 protein |
CTD |
PMID:18512786 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression |
ISO |
Ciprofloxacin results in increased expression of CSF2 protein |
CTD |
PMID:11125792 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
decreases expression |
ISO |
Ciprofloxacin results in decreased expression of CXCL2 protein |
CTD |
PMID:18197910 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cycs |
cytochrome c, somatic |
increases secretion |
EXP |
Ciprofloxacin results in increased secretion of CYCS protein |
CTD |
PMID:30273099 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
ISO |
[Ciprofloxacin results in decreased activity of CYP1A2 protein] which results in increased abundance of Clozapine; [Ciprofloxacin results in decreased activity of CYP1A2 protein] which results in increased abundance of norclozapine; Ciprofloxacin inhibits the reaction [CYP1A2 protein affects the metabolism of tizanidine]; Ciprofloxacin inhibits the reaction [CYP1A2 protein results in decreased methylation of Caffeine] |
CTD |
PMID:11145498 PMID:11151749 PMID:15592331 PMID:18816299 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases expression |
EXP |
Ciprofloxacin results in decreased expression of CYP2C11 mRNA |
CTD |
PMID:12621481 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Ciprofloxacin results in decreased activity of CYP3A4 protein |
CTD |
PMID:11145498 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
decreases expression |
EXP |
Ciprofloxacin results in decreased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:12621481 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Dhodh |
dihydroorotate dehydrogenase (quinone) |
multiple interactions decreases activity |
EXP |
Ciprofloxacin inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid] Ciprofloxacin results in decreased activity of DHODH protein |
CTD |
PMID:9776318 |
|
NCBI chr19:37,551,858...37,573,327
Ensembl chr19:37,558,177...37,591,654
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
decreases expression |
ISO |
Ciprofloxacin results in decreased expression of FGF15 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases response to substance |
ISO |
G6PD protein mutant form results in increased susceptibility to Ciprofloxacin |
CTD |
PMID:20127091 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
increases activity |
EXP |
Ciprofloxacin results in increased activity of GOT1 protein |
CTD |
PMID:30273099 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases activity |
ISO EXP |
[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein; Buthionine Sulfoximine promotes the reaction [[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein] Ciprofloxacin results in increased activity of GPT protein |
CTD |
PMID:29679711 PMID:30273099 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases expression |
ISO EXP |
Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]] [Ciprofloxacin co-treated with Cyclosporine] results in increased expression of IFNG mRNA; Ciprofloxacin inhibits the reaction [irinotecan promotes the reaction [Mitogens results in increased expression of IFNG protein]] Ciprofloxacin results in decreased expression of IFNG protein |
CTD |
PMID:16006447 PMID:16968468 PMID:18337667 PMID:19401694 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO EXP |
Ciprofloxacin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] Ciprofloxacin inhibits the reaction [irinotecan inhibits the reaction [Mitogens results in increased expression of IL10 protein]] |
CTD |
PMID:16939481 PMID:19401694 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]] |
CTD |
PMID:16968468 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
ISO EXP |
Ciprofloxacin affects the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of CXCL8 mRNA]; Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased activity of CEBPD mRNA]; Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of IL6 mRNA]; Ciprofloxacin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Ciprofloxacin inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; Ciprofloxacin promotes the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of CXCL8 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased secretion of MMP1 protein]; Ciprofloxacin promotes the reaction [IL1B protein results in increased secretion of MMP3 protein] Ciprofloxacin inhibits the reaction [irinotecan inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]] Ciprofloxacin results in decreased expression of IL1B protein |
CTD |
PMID:9267955 PMID:11052920 PMID:12428247 PMID:16148020 PMID:18197910 PMID:19401694 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
EXP |
Ciprofloxacin inhibits the reaction [irinotecan promotes the reaction [Mitogens results in increased expression of IL2 protein]] |
CTD |
PMID:19401694 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il3 |
interleukin 3 |
increases expression |
ISO |
Ciprofloxacin results in increased expression of IL3 mRNA; Ciprofloxacin results in increased expression of IL3 protein |
CTD |
PMID:11125792 |
|
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
ISO |
Ciprofloxacin results in decreased expression of IL4 protein |
CTD |
PMID:16006447 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of IL6 mRNA] Ciprofloxacin inhibits the reaction [irinotecan inhibits the reaction [Mitogens results in increased expression of IL6 protein]]; Ciprofloxacin inhibits the reaction [irinotecan promotes the reaction [Mitogens results in increased expression of IL6 protein]] |
CTD |
PMID:9267955 PMID:11052920 PMID:19401694 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects binding |
ISO |
Ciprofloxacin binds to KCNH2 protein |
CTD |
PMID:34058295 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of LCN2 mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
Ciprofloxacin results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:26947806 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
Ciprofloxacin results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:26947806 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mb |
myoglobin |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased secretion of MB protein |
CTD |
PMID:29679711 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
increases expression |
ISO |
Ciprofloxacin results in increased expression of MCL1 protein |
CTD |
PMID:32437906 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mir133b |
microRNA 133b |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR133B mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 9:23,098,134...23,098,217
Ensembl chr 9:23,098,134...23,098,217
|
|
G |
Mir206 |
microRNA 206 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR206 mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 9:23,094,249...23,094,332
Ensembl chr 9:23,094,249...23,094,332
|
|
G |
Mitf |
melanocyte inducing transcription factor |
decreases expression |
ISO |
Ciprofloxacin results in decreased expression of MITF protein |
CTD |
PMID:32437906 |
|
NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions increases expression |
ISO |
Ciprofloxacin promotes the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased secretion of MMP1 protein] Ciprofloxacin results in increased expression of MMP1 mRNA |
CTD |
PMID:12428247 PMID:16148020 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions decreases expression |
ISO |
Ciprofloxacin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Ciprofloxacin inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein] Ciprofloxacin results in decreased expression of MMP13 mRNA |
CTD |
PMID:16148020 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression increases activity |
EXP |
Ciprofloxacin results in increased expression of MMP2 mRNA Ciprofloxacin results in increased activity of MMP2 protein |
CTD |
PMID:21058936 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions increases expression |
ISO |
Ciprofloxacin promotes the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased secretion of MMP3 protein] Ciprofloxacin results in increased expression of MMP3 mRNA |
CTD |
PMID:12428247 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases activity increases expression |
EXP |
Ciprofloxacin results in increased activity of MMP9 protein Ciprofloxacin results in increased expression of MMP9 mRNA |
CTD |
PMID:21058936 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Ciprofloxacin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:24101390 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nanog |
Nanog homeobox |
increases expression |
ISO |
Ciprofloxacin results in increased expression of NANOG protein |
CTD |
PMID:26947806 |
|
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Nod2 |
nucleotide-binding oligomerization domain containing 2 |
decreases response to substance |
ISO |
NOD2 gene SNP results in decreased susceptibility to Ciprofloxacin |
CTD |
PMID:18371140 |
|
NCBI chr19:18,382,369...18,422,817
Ensembl chr19:18,382,439...18,417,177
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
Ciprofloxacin results in increased expression of NR0B2 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Ciprofloxacin results in increased cleavage of PARP1 protein |
CTD |
PMID:10741713 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
EXP |
Ciprofloxacin results in decreased activity of PGD protein |
CTD |
PMID:15558954 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Plk1 |
polo-like kinase 1 |
increases expression |
EXP |
Ciprofloxacin results in increased expression of PLK1 protein |
CTD |
PMID:18512786 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Pon1 |
paraoxonase 1 |
decreases activity |
ISO |
Ciprofloxacin results in decreased activity of PON1 protein |
CTD |
PMID:16880604 PMID:31581362 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
increases expression |
ISO |
Ciprofloxacin results in increased expression of POU5F1 protein |
CTD |
PMID:26947806 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Prom1 |
prominin 1 |
increases expression |
ISO |
Ciprofloxacin results in increased expression of PROM1 protein |
CTD |
PMID:26947806 |
|
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
|
|
G |
RT1-A2 |
RT1 class Ia, locus A2 |
affects expression |
ISO |
Ciprofloxacin affects the expression of HLA-E mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,870,939...4,910,183
|
|
G |
RT1-Db1 |
RT1 class II, locus Db1 |
affects expression |
ISO |
Ciprofloxacin affects the expression of HLA-DRB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258
|
|
G |
RT1-M3-1 |
RT1 class Ib, locus M3, gene 1 |
affects expression |
ISO |
Ciprofloxacin affects the expression of HLA-G mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
affects localization decreases expression |
ISO |
Ciprofloxacin affects the localization of SLC2A1 mRNA Ciprofloxacin results in decreased expression of SLC2A1 mRNA |
CTD |
PMID:19022360 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc51b |
SLC51 subunit beta |
decreases expression |
ISO |
Ciprofloxacin results in decreased expression of SLC51B mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
increases expression |
ISO |
Ciprofloxacin results in increased expression of SLCO1B2 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
decreases expression |
ISO |
Ciprofloxacin results in decreased expression of SNAI1 protein |
CTD |
PMID:26947806 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
decreases expression |
ISO |
Ciprofloxacin results in decreased expression of SNAI2 protein |
CTD |
PMID:26947806 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
decreases expression |
ISO |
Ciprofloxacin results in decreased expression of SOX2 protein |
CTD |
PMID:26947806 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression multiple interactions |
ISO EXP |
Ciprofloxacin results in increased expression of TGFB1 mRNA [Ciprofloxacin co-treated with Cyclosporine] results in decreased expression of TGFB1 mRNA |
CTD |
PMID:18337667 PMID:19371339 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
Ciprofloxacin affects the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of CXCL8 mRNA]; Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased activity of CEBPD mRNA]; Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of IL6 mRNA]; Ciprofloxacin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Ciprofloxacin promotes the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of CXCL8 mRNA]; wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]] [Ciprofloxacin co-treated with Cyclosporine] results in decreased expression of TNF mRNA; [irinotecan co-treated with Ciprofloxacin] promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Ciprofloxacin inhibits the reaction [irinotecan promotes the reaction [Mitogens results in increased expression of TNF protein]] Ciprofloxacin results in decreased expression of TNF protein |
CTD |
PMID:9267955 PMID:11052920 PMID:16939481 PMID:16968468 PMID:18197910 PMID:18337667 PMID:19401694 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Top1 |
DNA topoisomerase I |
multiple interactions |
ISO |
[Ciprofloxacin co-treated with Camptothecin] results in decreased activity of TOP1 protein |
CTD |
PMID:18191106 |
|
NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Top2a |
DNA topoisomerase II alpha |
affects binding multiple interactions |
ISO |
Ciprofloxacin binds to TOP2A protein [Ciprofloxacin binds to TOP2A protein] inhibits the reaction [Etoposide binds to TOP2A protein]; [Ciprofloxacin binds to TOP2A protein] inhibits the reaction [F14512 binds to TOP2A protein] |
CTD |
PMID:21413765 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Xirp1 |
xin actin-binding repeat containing 1 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of XIRP1 mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 8:119,744,778...119,757,547
Ensembl chr 8:119,747,419...119,757,349
|
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases expression |
ISO |
elvitegravir results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
increases expression |
ISO |
elvitegravir results in increased expression of FGF8 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 1:244,584,477...244,590,578
Ensembl chr 1:244,584,652...244,590,359
|
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
EXP |
Selenium inhibits the reaction [enrofloxacin results in decreased activity of CAT protein] |
CTD |
PMID:27083143 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects binding |
ISO |
Enrofloxacin binds to KCNH2 protein |
CTD |
PMID:34058295 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
Gcg |
glucagon |
increases secretion increases expression multiple interactions |
ISO EXP |
gatifloxacin results in increased secretion of GCG protein gatifloxacin results in increased expression of GCG protein [gatifloxacin co-treated with GCG protein] affects the secretion of INS1 protein; GCG protein affects the reaction [gatifloxacin results in decreased expression of INS2 mRNA]; GCG protein promotes the reaction [gatifloxacin affects the expression of GCGR mRNA] Diazoxide inhibits the reaction [gatifloxacin results in increased secretion of GCG protein] gatifloxacin results in increased expression of GCG mRNA |
CTD |
PMID:23200776 |
|
NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Gcgr |
glucagon receptor |
multiple interactions affects expression |
EXP |
GCG protein promotes the reaction [gatifloxacin affects the expression of GCGR mRNA] |
CTD |
PMID:23200776 |
|
NCBI chr10:105,808,474...105,816,641
Ensembl chr10:105,808,473...105,816,640
|
|
G |
Ins1 |
insulin 1 |
multiple interactions affects secretion |
EXP |
[Gatifloxacin co-treated with GCG protein] affects the secretion of INS1 protein Gatifloxacin affects the secretion of INS1 protein |
CTD |
PMID:23200776 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions decreases expression |
EXP |
GCG protein affects the reaction [gatifloxacin results in decreased expression of INS2 mRNA] |
CTD |
PMID:23200776 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
[Gatifloxacin binds to and results in decreased activity of KCNH2 protein] which results in decreased export of Potassium; Gatifloxacin binds to and results in decreased activity of KCNH2 protein |
CTD |
PMID:34058295 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression increases activity |
EXP |
Gatifloxacin results in increased expression of MMP2 mRNA Gatifloxacin results in increased activity of MMP2 protein |
CTD |
PMID:21058936 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression increases activity |
EXP |
Gatifloxacin results in increased expression of MMP9 mRNA Gatifloxacin results in increased activity of MMP9 protein |
CTD |
PMID:21058936 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Pcsk1 |
proprotein convertase subtilisin/kexin type 1 |
increases expression |
ISO |
gatifloxacin results in increased expression of PCSK1 mRNA |
CTD |
PMID:23200776 |
|
NCBI chr 2:4,395,543...4,442,434
Ensembl chr 2:4,395,543...4,442,434
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
Kynurenic Acid inhibits the reaction [ABCB11 protein results in increased uptake of Taurocholic Acid] |
CTD |
PMID:30639138 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
Kynurenic Acid inhibits the reaction [ABCC4 protein results in increased export of Methotrexate] |
CTD |
PMID:21483698 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Kynurenic Acid inhibits the reaction [ABCG2 protein results in increased export of estrone sulfate] |
CTD |
PMID:21483698 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases activity |
ISO |
AHR protein affects the reaction [[Kynurenic Acid co-treated with IL1B protein] results in increased expression of CYP1A1 mRNA]; AHR protein affects the reaction [[Kynurenic Acid co-treated with IL1B protein] results in increased expression of IL6 mRNA]; Kynurenic Acid binds to and results in increased activity of AHR protein Kynurenic Acid analog results in increased activity of AHR protein; Kynurenic Acid results in increased activity of AHR protein |
CTD |
PMID:20106948 PMID:27020609 PMID:28336214 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Kynurenic Acid |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression increases activity |
ISO |
[Kynurenic Acid co-treated with IL1B protein] results in increased expression of CYP1A1 mRNA; AHR protein affects the reaction [[Kynurenic Acid co-treated with IL1B protein] results in increased expression of CYP1A1 mRNA] Kynurenic Acid results in increased expression of CYP1A1 mRNA Kynurenic Acid results in increased activity of CYP1A1 protein |
CTD |
PMID:20106948 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
decreases secretion |
ISO |
Kynurenic Acid results in decreased secretion of FGF1 protein |
CTD |
PMID:16392031 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Gpr35 |
G protein-coupled receptor 35 |
multiple interactions |
ISO |
Kynurenic Acid binds to and results in increased activity of GPR35 protein |
CTD |
PMID:20826425 |
|
NCBI chr 9:93,527,165...93,539,573
Ensembl chr 9:93,527,127...93,539,299
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Kynurenic Acid co-treated with IL1B protein] results in increased expression of CYP1A1 mRNA; AHR protein affects the reaction [[Kynurenic Acid co-treated with IL1B protein] results in increased expression of CYP1A1 mRNA]; AHR protein affects the reaction [[Kynurenic Acid co-treated with IL1B protein] results in increased expression of IL6 mRNA]; IL1B protein promotes the reaction [Kynurenic Acid results in increased expression of IL6 mRNA] Kynurenic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; Kynurenic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL1B protein]; methyl 5-((tert-butylcarbamothioylhydrazinylidene)methyl)-1-(2,4-difluorophenyl)pyrazole-4-carboxylate inhibits the reaction [Kynurenic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]] |
CTD |
PMID:20106948 PMID:35123988 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
AHR protein affects the reaction [[Kynurenic Acid co-treated with IL1B protein] results in increased expression of IL6 mRNA]; IL1B protein promotes the reaction [Kynurenic Acid results in increased expression of IL6 mRNA] |
CTD |
PMID:20106948 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
Kynurenic Acid inhibits the reaction [[INS protein co-treated with Glucose] results in decreased chemical synthesis of Nitric Oxide]; Kynurenic Acid inhibits the reaction [[INS protein co-treated with Glucose] results in decreased expression of SLC2A3 protein] |
CTD |
PMID:28951307 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Kmo |
kynurenine 3-monooxygenase |
multiple interactions |
EXP |
[Ro 61-8048 results in decreased activity of KMO protein] which results in increased abundance of Kynurenic Acid |
CTD |
PMID:30151725 |
|
NCBI chr13:87,557,080...87,589,334
Ensembl chr13:87,557,286...87,588,881
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Kynurenic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein] |
CTD |
PMID:35123988 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Kynurenic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:35123988 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
Kynurenic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of OCLN protein] |
CTD |
PMID:35123988 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Kynurenic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein]; Kynurenic Acid promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of RELA protein] |
CTD |
PMID:35123988 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
multiple interactions |
ISO |
Kynurenic Acid inhibits the reaction [[INS protein co-treated with Glucose] results in decreased expression of SLC2A3 protein] |
CTD |
PMID:28951307 |
|
NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
Kynurenic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of TJP1 protein] |
CTD |
PMID:35123988 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Kynurenic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; Kynurenic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]; methyl 5-((tert-butylcarbamothioylhydrazinylidene)methyl)-1-(2,4-difluorophenyl)pyrazole-4-carboxylate inhibits the reaction [Kynurenic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]] |
CTD |
PMID:35123988 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects binding |
ISO |
lomefloxacin binds to KCNH2 protein |
CTD |
PMID:34058295 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression increases activity |
EXP |
lomefloxacin results in increased expression of MMP2 mRNA lomefloxacin results in increased activity of MMP2 protein |
CTD |
PMID:21058936 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression increases activity |
EXP |
lomefloxacin results in increased expression of MMP9 mRNA lomefloxacin results in increased activity of MMP9 protein |
CTD |
PMID:21058936 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
|
G |
Ifng |
interferon gamma |
decreases expression |
ISO |
moxifloxacin results in decreased expression of IFNG protein |
CTD |
PMID:16006447 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
decreases secretion |
ISO |
moxifloxacin results in decreased secretion of IL1B protein |
CTD |
PMID:16352735 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
ISO |
moxifloxacin results in decreased expression of IL4 protein |
CTD |
PMID:16006447 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
moxifloxacin results in decreased activity of KCNH2 protein |
CTD |
PMID:24052561 PMID:27553911 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
ISO |
moxifloxacin results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:16352735 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
ISO |
moxifloxacin results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:16352735 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases secretion decreases secretion |
ISO |
Moxifloxacin results in increased secretion of MMP1 protein Moxifloxacin results in decreased secretion of MMP1 protein |
CTD |
PMID:24890593 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases activity increases expression |
EXP |
Moxifloxacin results in increased activity of MMP2 protein Moxifloxacin results in increased expression of MMP2 mRNA |
CTD |
PMID:21058936 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
decreases secretion increases secretion |
ISO |
Moxifloxacin results in decreased secretion of MMP3 protein Moxifloxacin results in increased secretion of MMP3 protein |
CTD |
PMID:24890593 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases secretion increases expression increases activity |
ISO EXP |
Moxifloxacin results in decreased secretion of MMP9 protein Moxifloxacin results in increased expression of MMP9 mRNA Moxifloxacin results in increased activity of MMP9 protein |
CTD |
PMID:21058936 PMID:24890593 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Pon1 |
paraoxonase 1 |
decreases activity |
ISO |
Moxifloxacin results in decreased activity of PON1 protein |
CTD |
PMID:31581362 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases expression |
ISO |
moxifloxacin results in decreased expression of RELA protein |
CTD |
PMID:16352735 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion |
ISO |
moxifloxacin results in decreased secretion of TNF protein |
CTD |
PMID:16352735 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Top1 |
DNA topoisomerase I |
multiple interactions |
ISO |
[moxifloxacin co-treated with Camptothecin] results in decreased activity of TOP1 protein |
CTD |
PMID:18191106 |
|
NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of moxifloxacin |
CTD |
PMID:15769885 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of moxifloxacin |
CTD |
PMID:15769885 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of moxifloxacin |
CTD |
PMID:15769885 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
ISO |
Norfloxacin results in increased expression of AIFM1 protein |
CTD |
PMID:32320760 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
ISO |
Norfloxacin results in increased expression of BAD protein |
CTD |
PMID:32320760 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Norfloxacin results in increased expression of BAX protein |
CTD |
PMID:32320760 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Norfloxacin results in decreased expression of BCL2 protein |
CTD |
PMID:32320760 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp2 |
caspase 2 |
affects activity |
ISO |
Norfloxacin affects the activity of CASP2 protein |
CTD |
PMID:32320760 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp8 |
caspase 8 |
affects activity |
ISO |
Norfloxacin affects the activity of CASP8 protein |
CTD |
PMID:32320760 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects binding multiple interactions |
EXP |
Norfloxacin binds to CYP1A2 protein Norfloxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Phenacetin] |
CTD |
PMID:8905919 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Norfloxacin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Norfloxacin inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; Norfloxacin promotes the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Norfloxacin promotes the reaction [IL1B protein results in increased secretion of MMP1 protein] [biphenylylacetic acid co-treated with Norfloxacin] results in increased expression of IL1B mRNA; [biphenylylacetic acid co-treated with Norfloxacin] results in increased expression of IL1B protein |
CTD |
PMID:16148020 PMID:16824509 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects binding |
ISO |
Norfloxacin binds to KCNH2 protein |
CTD |
PMID:34058295 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
Norfloxacin promotes the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Norfloxacin promotes the reaction [IL1B protein results in increased secretion of MMP1 protein] |
CTD |
PMID:16148020 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions decreases expression |
ISO |
Norfloxacin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Norfloxacin inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein] Norfloxacin results in decreased expression of MMP13 mRNA |
CTD |
PMID:16148020 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases activity increases expression |
EXP |
Norfloxacin results in increased activity of MMP2 protein Norfloxacin results in increased expression of MMP2 mRNA |
CTD |
PMID:21058936 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression increases activity |
EXP |
Norfloxacin results in increased expression of MMP9 mRNA Norfloxacin results in increased activity of MMP9 protein |
CTD |
PMID:21058936 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
affects expression |
ISO |
Norfloxacin affects the expression of MR1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Norfloxacin inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases activity increases expression |
EXP |
sparfloxacin results in increased activity of MMP2 protein sparfloxacin results in increased expression of MMP2 mRNA |
CTD |
PMID:21058936 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases activity increases expression |
EXP |
sparfloxacin results in increased activity of MMP9 protein sparfloxacin results in increased expression of MMP9 mRNA |
CTD |
PMID:21058936 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
xanthurenic acid binds to and results in increased activity of AHR protein |
CTD |
PMID:20106948 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of xanthurenic acid |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|